Search

After an interim analysis, Corcept Therapeutics announced that their phase 2 study showed no change on the primary endpoint, the ALSFRS-R score. However, there does appear to be an effect on survival, which is why Corcept will continue the open-label phase (OLE).

Two weeks ago, the 35th edition of the International Symposium on ALS/MND took place. For this conference, researchers, healthcare professionals and patients (organisations) gathered from all over the world in Montréal, Canada.

The International Symposium is the biggest annual conference dedicated to ALS and MND research.

Sign up for our free newsletter

TRICALS provides two service package options: MAGNET, a complete all-in-one package, and TRICALS Support, which lets you select and combine individual services to tailor our support to your needs.

INARC hosts a full-day meeting during ENCALS 2025 on June 3rd

INARC satellite meeting June 3th, ENCALS 2025

Endorsed by TRICALS and ENCALS

The ALS Center at Department of Neurology, Oslo University Hospital conducts nationwide clinical studies, including both investigator-initiated and sponsor-initiated trials, alongside other research projects. Supporting 50–60 patients annually and 20+ new diagnoses each year, we focus on advancing ALS research while im...

Communications officer

Neurologist, Principel Investigator